The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Circulating tumor cell (CTC) genomic signatures of hormone therapy resistance in men with metastatic castration-resistant prostate cancer (mCRPC).
 
Santosh Gupta
No Relationships to Disclose
 
Susan Halabi
Employment - ASCO
Consulting or Advisory Role - Bayer; Eisai; Ferring
 
Gabor Kemeny
No Relationships to Disclose
 
Monika Anand
No Relationships to Disclose
 
David M. Nanus
Consulting or Advisory Role - Roche/Genentech
Research Funding - Boehringer Ingelheim (Inst); Novartis (Inst); Zenith Epigenetics (Inst)
 
Paraskevi Giannakakou
Employment - Novartis (I)
Stock and Other Ownership Interests - Novartis (I)
Research Funding - Sanofi
Patents, Royalties, Other Intellectual Property - International Patent Application DOCKET NO. 1676.083WO1 “Identifying Taxane Sensitivity in Prostate Cancer Patients” (Giannakakou, Plymate, co-inventors)
 
Daniel J. George
Leadership - Capio BioSciences
Honoraria - Acceleron Pharma; American Association for Cancer Research; Axess Oncology; Bayer; EMD Serono; Exelixis; Janssen Oncology; Millennium Medical Publishing; OncLive; Pfizer; Sanofi; UroToday
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Exelixis; Genentech; Innocrin Pharma; Janssen; Merck Sharp & Dohme; Myovant Sciences; Pfizer; Sanofi
Speakers' Bureau - Bayer; Exelixis; Sanofi
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Dendreon (Inst); Exelixis (Inst); Innocrin Pharma (Inst); Janssen Oncology (Inst); Novartis (Inst); Pfizer (Inst); Sanofi/Aventis (Inst)
Travel, Accommodations, Expenses - Bayer; Exelixis; Janssen Oncology; Merck; Pfizer; Sanofi
 
Simon Gregory
Consulting or Advisory Role - Pfizer
Research Funding - Janssen (Inst)
 
Andrew J. Armstrong
Honoraria - Dendreon; Janssen Oncology
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Janssen Biotech; Medivation; Pfizer; Sanofi
Speakers' Bureau - Bayer; Dendreon
Research Funding - Active Biotech (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Medivation (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst)
Travel, Accommodations, Expenses - Astellas Scientific and Medical Affairs Inc; Bayer; Dendreon; Janssen Biotech